DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Freemont Management S.A.

Freemont Management S.A. cut its stake in DexCom, Inc. (NASDAQ:DXCM) by 55.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,000 shares of the medical device company’s stock after selling 124,200 shares during the period. DexCom accounts for 1.6% of Freemont Management S.A.’s portfolio, making the stock its 21st largest position. Freemont Management S.A.’s holdings in DexCom were worth $12,409,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in DXCM. DSM Capital Partners LLC acquired a new stake in shares of DexCom during the fourth quarter worth $28,000. Valley National Advisers Inc. raised its holdings in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after purchasing an additional 103 shares during the period. MV Capital Management Inc. raised its holdings in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares during the period. Smithfield Trust Co raised its holdings in shares of DexCom by 103.1% during the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after purchasing an additional 165 shares during the period. Finally, Washington Trust Advisors Inc. raised its holdings in shares of DexCom by 120.6% during the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after purchasing an additional 193 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 629 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total value of $79,411.25. Following the completion of the transaction, the executive vice president now owns 68,212 shares in the company, valued at approximately $8,611,765. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the transaction, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 629 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the transaction, the executive vice president now owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The disclosure for this sale can be found here. Insiders sold 186,641 shares of company stock worth $25,217,707 in the last 90 days. Corporate insiders own 0.30% of the company’s stock.

DexCom Price Performance

DXCM traded up $1.77 on Friday, reaching $127.37. The company had a trading volume of 2,275,564 shares, compared to its average volume of 2,483,182. The company has a fifty day moving average of $132.96 and a 200-day moving average of $124.65. The company has a market capitalization of $50.65 billion, a P/E ratio of 82.17, a PEG ratio of 3.11 and a beta of 1.23. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a one year low of $74.75 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. As a group, equities research analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on DXCM shares. Canaccord Genuity Group increased their target price on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday. Raymond James increased their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Citigroup increased their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, Royal Bank of Canada initiated coverage on shares of DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average target price of $141.67.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.